Canadian association of gastroenterology position statement: Hip fracture and proton pump inhibitor therapy -a 2013 update

Canadian Journal of Gastroenterology

Volumn 27, Issue 10, 2013, Pages

  Moayyedi, Paul ^a   Yuan, Yuhong ^a   Leontiadis, Grigorios ^a  

^a CAG Clinical Affairs ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; STEROID;

ARTICLE; BONE DENSITY; DOSE RESPONSE; FRACTURE; HIP FRACTURE; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84885603176     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. http://www.healthycanadians.gc.ca/recall-Alert-rappel-Avis/hc-sc/2013/ 26523a-eng.php (Accessed July 7, 2013).
2. http://www.cag-Acg.org/uploads/position/cag-position-ppi-hip-fracture.pdf (Accessed July 7, 2013).
3. Hill AB. Environment and disease: Association or causation? Proc R Soc Med 1965;58:295-300.
4. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol 2008;103:2428-31.
5. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. (Pubitemid 44306164)
6. Yang YX, Lewis JD, Epstein S, Metz DC. Long-Term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53. (Pubitemid 46021498)
7. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-26.
8. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9.
9. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101.
10. Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: A population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19:1131-6.
11. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Def Synd 2011;57:205-10.
12. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: A population-based casecontrol study. Osteoporos Int 2011;22:903-10.
13. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 2011;342:d2238.
14. Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: Nested case-control analysis in a health-insured population. AIDS (London, England) 2012;26:1073-82.
15. Mazziotti G, Baracca M, Doga M, Porcelli T, Vescovi PP, Giustina A. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur J Endocrinol 2012;167:865-72.
16. Reyes C, Formiga F, Coderch M, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 2013;52:557-61.
17. Chiang CH, Liu CJ, Chen PJ, et al. Hip fracture and risk of acute myocardial infarction: A nationwide study. J Bone Miner Res 2013;28:404-11.
18. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9.
19. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteopor Int 2009;20:1989-98.
20. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-9.
21. Feldstein AC, Weycker D, Nichols GA, et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009;44:153-9.
22. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the Women's Health Initiative. Arch Intern Med 2010;170:765-71.
23. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998-1004.
24. Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: A prospective cohort study. BMJ 2012;344:e372.
25. Mello M, Weideman RA, Little BB, Weideman MW, Cryer B, Brown GR. Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci 2012;57:2416-22.
26. Munson JC, Wahl PM, Daniel G, Kimmel SE, Hennessy S. Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Safe 2012;21:366-74.
27. Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int 2012;23:277-84.
28. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD. The effect of proton pump inhibitors on fracture risk: Report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 2013;24:1161-8.
29. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PloS One 2011;6:e17217.
30. Targownik LE, Lix LM, Leung S, Leslie WD. Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
31. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: Nested case-control study. BMJ 2011;342:d2238.
32. Gage BF, Birman-Deych E, Radfor MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: Results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006;166:241-6. (Pubitemid 43144951)
33. http://www.shef.ac.uk/FRAX/(Accessed July 7, 2013).